Zlepšení péče prostřednictvím výzkumu azithromycinu pro kojence v Africe (ICARIA)
Hodnocení vlivu intermitentní preventivní léčby azithromycinem plus na dětskou úmrtnost v rámci rozšířeného programu imunizace v Sierra Leone
Infectious diseases are among the most common causes of mortality in the over 2.5 million children under 5 years of age (U5) who died in 2018 in sub-Saharan Africa (SSA). New approaches to treatment and prevention of these diseases are needed to increase child survival. Sierra Leone has one of the highest rates of under-five child mortality in the world. It is estimated that 32,000 children die each year, the leading causes being neonatal conditions, malaria, pneumonia and diarrhea. In Sierra Leone, the available information on malaria indicates that it accounts for 38% of deaths among under-five children. Reducing the prevalence and impact of the disease among the general population is a major priority of the Ministry of Health and Sanitation (MoHS) of Sierra Leone .
Intermittent Preventative Treatment in infants (IPTi) - the administration of a full course antimalarial treatment to infants at individual timepoints regardless of infection status- has been shown to reduce clinical malaria and anemia in infants in the first year of life . When delivered alongside the Expanded Program on Immunization (EPI), IPTi with Sulphadoxine-pyrimethamine (SP) is a highly cost-effective intervention. . Sierra Leone is currently the only country that implements nationwide the World Health Organization's (WHO) IPTi guideline, which is administered within the first year of life. However, its benefit when expanded into the second year of life remains unknown. Taking the advantage of the inclusion in the EPI program of a booster dose of measles vaccine at 15 months of age, the ICARIA trial will also assess the efficacy of adding a dose of IPTi-SP at this age.
Recent studies show that azithromycin (AZi) - a macrolide antibiotic with some antimalarial effect- is associated with a significant reduction in childhood mortality when used in mass drug administration (MDA) for trachoma elimination in areas of sub-Saharan Africa (SSA) with child mortality rates far beyond Sustainable Development Goals , . However, despite the potential benefit of the intervention several fundamental scientific questions need to be answered before it can be recommended for large-scale implementation.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
In order to generate the conclusive evidence needed to inform policy and accelerate the implementation of this intervention, we propose to carry out a large-scale clinical trial on the impact on all-cause mortality up to 18 months of age of AZi administration through EPI. The potential development of antibiotic and SP resistance, AZi and SP interactions with routine immunizations, as well as the safety and the impact on the health system will be all assessed in the ICARIA trial.
To provide the evidence needed to inform policy and practice and to accelerate the implementation of this intervention, a large-scale clinical trial on the impact on all-cause mortality up to 18 months of age of AZi administration through the World Health Organisation Expanded Program on Immunisation (EPI) will be carried out in Sierra Leone. The clinical trial will be individually randomised, placebo-controlled with a factorial design whereby AZi will be administered alongside routine preventive health interventions of the EPI, such as immunisations and Intermittent Preventive Treatment in infants (IPTi), which is recommended by the WHO for malaria prevention in this age group. The potential development of antibiotic resistance, the interactions with routine immunisations, the safety and the impact on the health system of AZi administration will be all assessed in this trial.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Freetown, Sierra Leone
- College of Medicine and Allied Health Sciences
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Parents/guardians have signed the informed consent
- Permanent residence in the study area-health facility catchment area
- Without known allergies to or contraindications to macrolides
- Without known allergies to or contraindications to SP
- Agreement to complete the EPI scheme at the recruitment health facility
- Parents/guardians agree to participate
Exclusion Criteria:
- Residence outside the study area or planning to move out in the following 12 months from enrolment
- Known history of allergy or contraindications to macrolides and/or SP
- Known history of allergy or contraindications to SP
- With signs of any acute illness at the time of recruitment
- Participating in other intervention studies
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Aktivní komparátor: Group 1
AZi at DTP-1 visit at 6 weeks of age, AZi (plus IPTi) at measles visit at 9 months of age and AZi (plus IPTi) at measles booster visit at 15 months of age. |
Administration of azithromycin during the first 15 months of life through the Expanded Program on Immunisation
Ostatní jména:
|
|
Komparátor placeba: Group 2
Placebo at DTP-1 visit at 6 weeks of age, placebo (plus IPTi) at measles visit at 9 months of age and placebo (plus IPTi) at measles booster visit at 15 months of age. |
Administration of placebo during the first 15 months of life through the Expanded Program on Immunisation |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The rate of all-cause mortality
Časové okno: 18 months of age
|
all-cause mortality rate at 18 months of age |
18 months of age
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The cause-specific mortality rate
Časové okno: 18 months of age
|
Cause-specific mortality rate at 18 months of age |
18 months of age
|
|
Malaria related mortality
Časové okno: 18 month of age
|
Malaria related mortality at 18 months of age |
18 month of age
|
|
Incidence of all-cause hospital admissions
Časové okno: Through study completion, 36 months
|
Incidence of all-cause hospital admissions |
Through study completion, 36 months
|
|
Incidence of all-cause outpatient attendances
Časové okno: Through study completion, 36 months
|
Incidence of all-cause outpatient attendances at the health facilities |
Through study completion, 36 months
|
|
Incidence of confirmed (RDT positive) malaria hospital admissions
Časové okno: Through study completion, 36 months
|
Incidence of confirmed (RDT positive) malaria hospital admissions at all health facilities |
Through study completion, 36 months
|
|
Incidence of confirmed (blood smear positive/RDT positive) malaria hospital admissions
Časové okno: Through study completion, 36 months
|
Incidence of confirmed (blood smear positive/RDT positive) malaria hospital admissions at all health facilities |
Through study completion, 36 months
|
|
Frequency and severity of drug adverse reactions
Časové okno: Through study completion, 36 months
|
Frequency and severity of drug adverse reactions throughout the trial |
Through study completion, 36 months
|
|
Prevalence of macrolide resistance in nasopharyngeal isolates
Časové okno: Through study completion, 36 months
|
Prevalence of macrolide resistance in nasopharyngeal isolates |
Through study completion, 36 months
|
|
Prevalence of macrolide resistance in the gut bacteria
Časové okno: Through study completion, 36 months
|
Prevalence of macrolide resistance in the gut bacteria |
Through study completion, 36 months
|
|
Proportion of children with protective antibody responses to specific routine EPI immunizations (measles and yellow fever)
Časové okno: Through study completion, 36 months
|
Proportion of children with protective antibody responses to specific routine EPI |
Through study completion, 36 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Clara Menendez, MD, PhD, Barcelona Institute for Global Health
Publikace a užitečné odkazy
Obecné publikace
- Chen H, Owusu-Kyei K, Fombah AE, Williams J, Garcia-Fernandez C, Rovira-Vallbona E, Bofill A, Quinto L, Figueroa-Romero A, Mac-Abdul F, Samai M, Mayor A, Menendez C. Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone. Gates Open Res. 2025 Oct 8;9:81. doi: 10.12688/gatesopenres.16367.1. eCollection 2025.
- Owusu-Kyei K, Chen H, Chileshe M, Quinto L, Sibley M, Figueroa-Romero A, Llach M, Ramirez M, Bofill A, Samai M, Menendez C; ICARIA Trial Team. Impact of oral azithromycin and intermittent preventive treatment with sulfadoxine-pyrimethamine regimen on child mortality in Sierra Leone: trial protocol for a randomised, two-arm, double-blinded, placebo-controlled clinical trial (ICARIA). Trials. 2024 Sep 27;25(1):626. doi: 10.1186/s13063-024-08443-9.
- Chen H, Montero-Vale M, Owusu-Kyei K, Lara-Munoz A, Rubio-Garcia E, de Pedro-Jove R, Guiral E, Chileshe MN, Williams J, Bofill A, Samai M, Casals-Pascual C, Vila J, Menendez C. Early-life carriage and antibiotic resistance of Streptococcus pneumoniae in infants from Sierra Leone. Front Microbiol. 2026 May 22;17:1822296. doi: 10.3389/fmicb.2026.1822296. eCollection 2026.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- ICARIA
- OPP1196642 (Jiné číslo grantu/financování: Bill & Melinda Gates Foundation)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .